Eledon Pharmaceuticals Inc
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for C… Read more
Eledon Pharmaceuticals Inc (ELDN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.409x
Based on the latest financial reports, Eledon Pharmaceuticals Inc (ELDN) has a cash flow conversion efficiency ratio of -0.409x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.48 Million) by net assets ($35.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Eledon Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Eledon Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Eledon Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eledon Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Dorsel Holdings Ltd
TA:DRSH
|
0.011x |
|
IDUN INDUSTRIER AB B
F:1W6
|
N/A |
|
Man Infraconstruction Limited
NSE:MANINFRA
|
0.007x |
|
Al Aqar Healthcare Reit
KLSE:5116
|
0.052x |
|
Gencor Industries Inc
NYSE MKT:GENC
|
0.052x |
|
Fifth Era Acquisition Corp I Class A Ordinary Shares
NASDAQ:FERA
|
-0.001x |
|
BNC Korea Co. Ltd
KQ:256840
|
-0.008x |
|
Sagimet Biosciences Inc. Series A Common Stock
NASDAQ:SGMT
|
-0.085x |
Annual Cash Flow Conversion Efficiency for Eledon Pharmaceuticals Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Eledon Pharmaceuticals Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $118.14 Million | $-47.27 Million | -0.400x | +15.56% |
| 2023-12-31 | $83.42 Million | $-39.53 Million | -0.474x | -40.34% |
| 2022-12-31 | $84.18 Million | $-28.42 Million | -0.338x | -91.51% |
| 2021-12-31 | $164.00 Million | $-28.91 Million | -0.176x | -120.90% |
| 2020-12-31 | $190.60 Million | $-15.21 Million | -0.080x | +94.55% |
| 2019-12-31 | $9.46 Million | $-13.86 Million | -1.464x | -78.40% |
| 2018-12-31 | $14.49 Million | $-11.89 Million | -0.821x | -6.84% |
| 2017-12-31 | $19.45 Million | $-14.94 Million | -0.768x | +43.51% |
| 2016-12-31 | $26.86 Million | $-36.52 Million | -1.360x | -103.53% |
| 2015-12-31 | $61.72 Million | $-41.24 Million | -0.668x | -227.38% |
| 2014-12-31 | $103.50 Million | $-21.12 Million | -0.204x | -172.87% |
| 2013-12-31 | $-55.27 Million | $-15.48 Million | 0.280x | +19.72% |
| 2012-12-31 | $-39.90 Million | $-9.33 Million | 0.234x | -- |